Matches in Wikidata for { <http://www.wikidata.org/entity/Q92287110> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q92287110 description "article scientifique publié en 2019" @default.
- Q92287110 description "artículu científicu espublizáu n'abril de 2019" @default.
- Q92287110 description "im April 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92287110 description "scientific article published on 01 April 2019" @default.
- Q92287110 description "wetenschappelijk artikel" @default.
- Q92287110 description "наукова стаття, опублікована 1 квітня 2019" @default.
- Q92287110 name "Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion" @default.
- Q92287110 name "Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion" @default.
- Q92287110 type Item @default.
- Q92287110 label "Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion" @default.
- Q92287110 label "Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion" @default.
- Q92287110 prefLabel "Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion" @default.
- Q92287110 prefLabel "Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion" @default.
- Q92287110 P1433 Q92287110-310A2F7A-6164-49C3-9896-B0562E148893 @default.
- Q92287110 P1476 Q92287110-0434ADBA-BC64-4E80-9BE1-AEA4FD39A001 @default.
- Q92287110 P2093 Q92287110-22CBD5DD-CB43-46C8-8F20-2B0A5B2D058F @default.
- Q92287110 P2093 Q92287110-40C9A6CF-A83E-4418-8D9D-2238061B7D11 @default.
- Q92287110 P2093 Q92287110-A46C22E2-B24E-48FF-9CF2-70EE9C265425 @default.
- Q92287110 P2093 Q92287110-DA04D089-939B-414D-9AD2-9555C3BA6873 @default.
- Q92287110 P2093 Q92287110-F7CAABCA-DBE2-4B48-BC3C-4A4B0394F5D5 @default.
- Q92287110 P304 Q92287110-A97A571E-2769-4E20-8324-73D571357F7B @default.
- Q92287110 P31 Q92287110-73FCEFEA-48E3-43B7-90A0-CCCEDA28F666 @default.
- Q92287110 P356 Q92287110-1D520650-D9BD-4221-B26A-27E73C2043B4 @default.
- Q92287110 P433 Q92287110-8377886B-3FF3-4A17-8B44-25A94DCA75F4 @default.
- Q92287110 P478 Q92287110-DA121DDA-E516-4B25-851C-F4B62EAB6D6F @default.
- Q92287110 P577 Q92287110-1C50BE7B-31F0-4038-8EB4-F9A8A0EED4BA @default.
- Q92287110 P698 Q92287110-FB1F77A4-7E7C-4F0F-A51E-77FB17AAB977 @default.
- Q92287110 P921 Q92287110-0D33C900-57DE-410E-8A74-74A7B3C6AAD1 @default.
- Q92287110 P356 ZXZ013 @default.
- Q92287110 P698 31361865 @default.
- Q92287110 P1433 Q15754037 @default.
- Q92287110 P1476 "Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion" @default.
- Q92287110 P2093 "Brittany M Elgersma" @default.
- Q92287110 P2093 "Kiara M Oltman" @default.
- Q92287110 P2093 "Michael P Gulseth" @default.
- Q92287110 P2093 "Sara Zochert" @default.
- Q92287110 P2093 "Thaddaus R Hellwig" @default.
- Q92287110 P304 "505-511" @default.
- Q92287110 P31 Q13442814 @default.
- Q92287110 P356 "10.1093/AJHP/ZXZ013" @default.
- Q92287110 P433 "8" @default.
- Q92287110 P478 "76" @default.
- Q92287110 P577 "2019-04-01T00:00:00Z" @default.
- Q92287110 P698 "31361865" @default.
- Q92287110 P921 Q424337 @default.